%0 Journal Article
%T ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease.
%A Hamad N
%A Bilmon I
%A Chee L
%A Henden A
%A Johnston A
%A Purtill D
%A Bajel A
%A Tey SK
%A Yeung D
%A Cole T
%A Lewis C
%A Butler J
%J Intern Med J
%V 53
%N 12
%D 2023 Dec 28
%M 38014511
%F 2.611
%R 10.1111/imj.16255
%X This position paper provides an overview of the assessment and management of both acute and chronic graft-versus-host disease (GvHD). There is a focus on the use of ruxolitinib, a selective inhibitor of Janus kinase (JAK)1 and JAK2, for the treatment of corticosteroid-refractory and corticosteroid-dependent GvHD.